Novo Nordisk licensed Valo's Opal platform and three preclinical programs for cardiometabolic disease.
Novo Nordisk wanted to speed discovery in cardiometabolic disease. Valo's Opal predicts pharmacokinetics, ADME and toxicity and uses real-world human data and tissue modelling. The article reports $60M initial payment, up to $2.7B total across up to 11 programs.
Valo Health is an AI drug discovery company whose Opal platform combines real-world patient data and computation to find targets and small molecules for partners.
This sits in the Build stage of the AI use-case lifecycle: Named examples from the foundation-model labs and platforms pharma teams use to actually construct, train and generate the model or application.
Published by Valo Health on its own site — read the original case study on pharmaphorum.com ↗
Note: Trade press (pharmaphorum) coverage; Valo's own page not fetched.
Related use cases
- 01Valo and nference began a multi-year collaboration linking Opal with nference's agentic AI platform and federated patient data.
- 02Valo and Charles River's Logica platform identified an advanceable candidate for lupus and autoimmune disease.
- 03Valo and KSM partnered to analyse Israel's largest biobank with Opal for preventive care and personalised medicine.
- 04OpenAI's dedicated healthcare vertical page/launch post.
- 05Frontier reasoning model built for biology, drug discovery and translational medicine; named qualified customers include Amgen, Moderna, Allen Institute, and Thermo Fisher Scientific.
- 06follow-up update to the life-sciences model.